RxDoctor Payments Data

Ghulam Murtaza

Interventional Cardiology · Aiken, SCNPI 1114308814

Payments from drug & device makers

$2,009in general payments, 2019–2025

Across 54 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$801
  • Pfizer$292
  • Abiomed$183
  • Amgen$169
  • Novartis$152
  • Boston Scientific$123
  • plus $289 from 9 others

What the payments were for

  • Travel & lodging$80140%
  • Food & beverage$1,20860%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,009 in reported general payments places this provider in the 5th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$131,827
Medicare patients
554
Services billed
1,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban215$204,860
EntrestoSacubitril/Valsartan82$91,639
BrilintaTicagrelor62$37,931
FarxigaDapagliflozin Propanediol39$34,297
XareltoRivaroxaban27$28,415
Repatha SureclickEvolocumab14$9,749
Metoprolol Succinate166$2,099
Rosuvastatin Calcium107$1,757
Carvedilol155$1,728
Atorvastatin Calcium122$1,557
Isosorbide Mononitrate ErIsosorbide Mononitrate91$1,132
ClopidogrelClopidogrel Bisulfate71$1,068
Amlodipine Besylate150$1,020
Chlorthalidone30$961
Nifedipine ErNifedipine20$952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$292$204,860215 claims
NovartisEntresto$152$91,63982 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Aiken

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →